By: PRLog
DCA and Avemar now shows promise against both AML and CLL Leukemia
PR Log - Jun 08, 2012 - Leukemia is known to be one of the most pernicious forms of cancer.  Yet combining two mild, non-chemotherapy agents, dramatic clinical (in vivo) results have been achieved.

As a follow up to a previous report of DCA and Avemar working against AML Leukemia, a new case has surfaced of the protocol working against Chronic lymphocytic leukemia (CLL) Leukemia.

   The term “chronic” in chronic lymphocytic leukemia comes from the fact that it typically progresses more slowly than other types of leukemia. The term “lymphocytic” in chronic lymphocytic leukemia comes from the cells affected by the disease — a group of white blood cells called lymphocytes, which help your body fight infection.

   – http://www.mayoclinic.com/health/chronic-lymphocytic-leuk...

   The patient initially responded favourably to DCA alone, but when Avemar was added, the response was dramatically better (measured by the cell counts).

   – Dr. Akbar Khan, Medicor Cancer Centres

Here is the original story about AML Leukemia:
http://www.martincwiner.com/dca-and-avemar-show-clinical-...

Here is the original story about CLL Leukemia:
http://www.martincwiner.com/dca-and-avemar-show-clinical-...

Here is the original video describing the protocol:
http://www.martincwiner.com/dca-and-avemar-a-theoretical-protocol-for-cancer/

Read Full Story - DCA and Avemar now shows promise against both AML and CLL Leukemia | More news from this source

Press release distribution by PRLog

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here